Katy Beckermann

NCCN Guidelines Insights: Kidney Cancer, Version 1.2021

Robert J. Motzer, Eric Jonasch, Shawna Boyle et al. · Journal of the National Comprehensive Cancer Network · 2020 · 247 citations · Full text

Urology, Genitourinary Cancer, Stage Iv Rcc +8

TiNivo-2: A phase 3, randomized, controlled, multicenter, open-label study to compare tivozanib in combination with nivolumab to tivozanib monotherapy in subjects with renal cell carcinoma who have progressed following one or two lines of therapy where one line has an immune checkpoint inhibitor.

Toni K. Choueiri, Laurence Albigès, Hans J. Hammers et al. · Journal of Clinical Oncology · 2022 · 17 citations

Pharmacotherapy, Metronomic Chemotherapy, Immunotherapy +17

Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC).

Yu‐Wei Chen, Katy Beckermann, Scott M. Haake et al. · Journal of Clinical Oncology · 2023 · 15 citations

Ccrcc Tumors, Cancer Management, Renal Pathology +22

Targeting metabolic dysregulation of T cells in kidney cancer.

Katy Beckermann, Kirsten Young, Rachel A. Hongo et al. · Journal of Clinical Oncology · 2020 · 14 citations

Initial results from the phase 1 study of ARO-HIF2 to silence HIF2-alpha in patients with advanced ccRCC (AROHIF21001).

James Brugarolas, Katy Beckermann, Brian I. Rini et al. · Journal of Clinical Oncology · 2022 · 13 citations

Advanced Ccrcc, Immunology, Renal Inflammation +20